title: Inadequate glycaemic control and antidiabetic therapy among inpatients with type 2 diabetes in Guangdong Province of China.
abstract: BACKGROUND
  Diabetes mellitus has become epidemic in recent years in China. We investigated the prevalence of hyperglycaemia and inadequate glycaemic control among type 2 diabetic inpatients from ten university teaching hospitals in Guangdong Province, China.
  
  
  METHODS
  Inadequate glycaemic control in diabetic patients was defined as HbA1c = 6.5%. Therapeutic regimens included no-intervention, lifestyle only, oral antiglycemic agents (OA), insulin plus OA (insulin + OA), or insulin only. Antidiabetic managements included monotherapy, double therapy, triple or quadruple therapy.
  
  
  RESULTS
  Among 493 diabetic inpatients with known history, 75% had HbA1c = 6.5%. Inadequate glucose control rates were more frequently seen in patients on insulin + OA regimen (97%) than on OA regimen (71%) (P < 0.001), and more frequent in patients on combination therapy (81% - 96%) than monotherapy (75%) (P < 0.05). Patients on insulin differed significantly from patients on OA by mean HbA1c, glycemic control rate, diabetes duration, microvascular complications, and BMI (P < 0.01).
  
  
  CONCLUSIONS
  This study showed that glycaemic control of type 2 diabetic patients deteriorated for patients who received insulin and initiation time of insulin was usually delayed. It is up to clinicians to move from the traditional stepwise therapy to a more active and early combination antidiabetic therapy to provide better glucose control.
authors.affiliation: Department of Endocrinology, First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong 510080, China.
authors.forename: Yan
authors.initials: Y
authors.lastname: Bi
authors.forename: Jin-hua
authors.initials: JH
authors.lastname: Yan
authors.forename: Zhi-hong
authors.initials: ZH
authors.lastname: Liao
authors.forename: Yan-bing
authors.initials: YB
authors.lastname: Li
authors.forename: Long-yi
authors.initials: LY
authors.lastname: Zeng
authors.forename: Kuan-xiao
authors.initials: KX
authors.lastname: Tang
authors.forename: Yao-ming
authors.initials: YM
authors.lastname: Xue
authors.forename: Hua-zhang
authors.initials: HZ
authors.lastname: Yang
authors.forename: Lu
authors.initials: L
authors.lastname: Li
authors.forename: De-hong
authors.initials: DH
authors.lastname: Cai
authors.forename: Ge
authors.initials: G
authors.lastname: Wu
authors.forename: Fan
authors.initials: F
authors.lastname: Zhang
authors.forename: Shao-da
authors.initials: SD
authors.lastname: Lin
authors.forename: Zheng-hua
authors.initials: ZH
authors.lastname: Xiao
authors.forename: Da-long
authors.initials: DL
authors.lastname: Zhu
authors.forename: Jian-ping
authors.initials: JP
authors.lastname: Weng
mesh_terms: D000368:Aged; D002681:China / Q000453:epidemiology; D003924:Diabetes Mellitus, Type 2 / Q000097:blood* / Q000188:drug therapy*; D005260:Female; D006442:Glycated Hemoglobin / Q000032:analysis; D006801:Humans; D006943:Hyperglycemia / Q000453:epidemiology; D007004:Hypoglycemic Agents / Q000008:administration & dosage; D007297:Inpatients; D008297:Male; D008875:Middle Aged
chemical_list: D006442:Glycated Hemoglobin; D007004:Hypoglycemic Agents; C517652:hemoglobin A1c protein, human